Utilizing Rapid Molecular Tests (RMT/RIF) in Tuberculosis Drug-Sensitive/Resistant Discovery in Indonesia: A Pilot Study

Authors

Maria Holly Herawati, Public Health and Nutrition Research Center, Health Organization Research, The National Research and Innovation AgencyFollow
Dasuki Dasuki, Public Health and Nutrition Research Center, Health Organization Research, The National Research and Innovation AgencyFollow
Dina Bisara Lolong, Public Health and Nutrition Research Center, Health Organization Research, The National Research and Innovation AgencyFollow
Mirna Widiyanti, Public Health and Nutrition Research Center, Health Organization Research, The National Research and Innovation AgencyFollow
Betty Roosihermiatie, Public Health and Nutrition Research Center, Health Organization Research, The National Research and Innovation AgencyFollow
Ria Yuda Permata, Public Health and Nutrition Research Center, Health Organization Research, The National Research and Innovation AgencyFollow
Raflizar Raflizar, Public Health and Nutrition Research Center, Health Organization Research, The National Research and Innovation AgencyFollow
Ferry Ahmadi, Public Health and Nutrition Research Center, Health Organization Research, The National Research and Innovation AgencyFollow
Hadi Supratikta, Public Health and Nutrition Research Center, Health Organization Research, The National Research and Innovation AgencyFollow
Meita Veruswati, Department of Public Health, Faculty of Health Sciences, University of Muhammadiyah Prof. Dr. HAMKA (UHAMKA)Follow

Abstract

The underdiagnosis and underreporting of tuberculosis (TB) indicators are unresolved problems. The rapid molecular test (RMT) is one of the breakthroughs for TB case finding by using safer and more sensitive equipment; it is even believed to help find drug-resistant TB. The results of several webinars held regularly by a TB program as well as its evaluation and the use of RMT formed the basis of this study. This initial pilot study aimed to provide an overview of case finding for both drug-sensitive and drug-resistant TB using RMT. A cross-sectional study was conducted on samples in several provinces in Indonesia that have used RMT, both in remote or non-remote island borders areas and fiscal capacity. Regarding the use of RMT for drug-sensitive TB case finding, the largest contributors were males aged above 15 years, while in the drug-resistant TB case finding group, the biggest contributor was the use of RMT in 2017 and 2018. Overall, the findings could only describe the situation in the study area. The use of RMT in drug-sensitive TB case finding would be maximized if the detected cases are males aged above 15 years, while RMT can help find cases of drug-resistant TB.

References

1. World Health Organization. Global Tuberculosis Reports. Geneva: World Health Organization; 2015.

2. Kementerian Kesehatan Republik Indonesia. Pedoman Nasional Pengendalian Tuberkulosis. Jakarta: Kementerian Kesehatan Republik Indonesia; 2011.

3. Badan Penelitian dan Pengembangan Kesehatan. Hasil Utama Riskesdas 2007. Jakarta: Kementerian Kesehatan Republik Indonesia; 2008.

4. Badan Penelitian dan Pengembangan Kesehatan. Hasil Utama Riskesdas 2010. Jakarta: Kementerian Kesehatan Republik Indonesia; 2010.

5. Badan Penelitian dan Pengembangan Kesehatan. Hasil Utama Riskesdas 2013. Jakarta: Kementerian Kesehatan Republik Indonesia; 2013.

6. World Health Organization. Automated Real-time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System: Policy Statement. Geneva: World Health Organization; 2011.

7. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: A multicentre implementation study. Lancet. 2011; 377 (9776): 1495-1505. DOI: 10.1016/S0140-6736(11)60438-8

8. Rachow A, Zumla A, Heinrich N, et al. Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay--a clinical validation study. PLoS One. 2011; 6 (6): e20458. DOI: 10.1371/journal.pone.0020458

9. Sekadde MP, Wobudeya E, Joloba ML, et al. Evaluation of the Xpert MTB/RIF test for the diagnosis of childhood pulmonary tuberculosis in Uganda: A cross-sectional diagnostic study. BMC Infect Dis. 2013; 13: 133. DOI: 10.1186/1471-2334-13-133

10. World Health Organization. Xpert MTB/RIF implementation manual:Technical and operational 'How-to': Practical Considerations. France: GPS Publishing; 2014.

11. Menteri Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Nomor 67 Tahun 2016 Tentang Penanggulangan Tuberkulosis. Jakarta: Kementerian Kesehatan Republik Indonesia; 2016.

12. Direktorat Pencegahan dan Pengendalian Penyakit Menular. Evaluasi Capaian Program P2TBC dan Strategi Percepatan Penanggulangan Nasional. Jakarta: Kementerian Kesehatan Republik Indonesia; 2021.

13. Lolong DB. Laporan Studi Evaluasi deteksi kasus TB dengan alat RMT di Indonesia Tahun 2018. Jakarta: Kementerian Kesehatan Republik Indonesia; 2018.

14. Dougherty C. Introduction to econometrics. 2nd ed. New York: Oxford University Press; 2002.

15. Ghozali I. Aplikasi Analisis Multivariate dengan Program IBM SPSS 23. 8th ed. Semarang: Badan Penerbit Universitas Diponegoro; 2016.

16. Sazkiah ER, Hardja BAR. Distribusi Penyakit Tuberkulosis Berdasarkan Jenis Kelamin dan Usia di Rumah Sakit Sri Pamela. Ber Kedokt Masy. 2018; 34 (11). DOI: 10.22146/bkm.39866

17. Herawati MH. Alternatif Penanggulangan Tuberkulosis (TBC) Wilayah Indonesia di Luar Sumatra dan Jawa-Bali. Jakarta: LIPI Press; 2021.

18. Herawati MH. Model Evaluasi Program Pengendalian TB di Indonesia (Data Rifaskes dan Data Program TB) [Dissertation]. Depok: Universitas Indonesia; 2016.

19. Putri D, Miliyani S. Kegagalan Penjaringan Suspek Tuberkulosis Paru pada P2TB Puskesmas di Kabupaten Jember Tahun 2015. Jember: Universitas Jember; 2017.

Recommended Citation

Herawati MH , Dasuki D , Lolong DB , et al. Utilizing Rapid Molecular Tests (RMT/RIF) in Tuberculosis Drug-Sensitive/Resistant Discovery in Indonesia: A Pilot Study. Kesmas. 2023; 18(5): 112-116
DOI: 10.21109/kesmas.v18isp1.6875
Available at: https://scholarhub.ui.ac.id/kesmas/vol18/iss5/20